Skip to main content
. Author manuscript; available in PMC: 2022 Aug 1.
Published in final edited form as: Adv Healthc Mater. 2021 Jan 14;10(15):e2001894. doi: 10.1002/adhm.202001894

Figure 1: Selection of C6-KH pBAE polymer.

Figure 1:

(A) Structure and synthetic scheme of oligopeptide-modified pBAEs. R” terminal can be arginine-, lysine-, histidine-, glutamic acid- or aspartic acid-oligopeptide. (B and C) Biophysical characterization of pBAE NPs. (B) Average hydrodynamic diameter, polydispersity, (C) and zeta potential of pBAE:anti-miR-712 nanoparticles prepared at 75:1 polymer:anti-miR-712 ratio (w/w) with different oligopeptide-modified pBAE polymers are shown. (D) Cellular uptake of oligopeptide-modified pBAEs using fluorescent-labelled anti-miR (anti-miR-Cy3) at a final concentration of 200nM in iMAECs. (E) Fluorescent images of iMAECs using lysine/histidine-modified pBAE (C6-KH). Scale bar: 50 μm. Data are represented as mean ± SEM (n = 3). Multiple comparisons among groups were determined using one-way ANOVA followed by a post-hoc test. P-value: *p < 0.05, **p < 0.01, ***p < 0.001.